1. Home
  2. KGS vs CRNX Comparison

KGS vs CRNX Comparison

Compare KGS & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kodiak Gas Services Inc.

KGS

Kodiak Gas Services Inc.

HOLD

Current Price

$56.69

Market Cap

3.5B

Sector

N/A

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$35.81

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KGS
CRNX
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.9B
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
KGS
CRNX
Price
$56.69
$35.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$52.50
$74.78
AVG Volume (30 Days)
1.3M
885.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
3.53%
N/A
EPS Growth
58.93
N/A
EPS
0.89
N/A
Revenue
$1,308,100,000.00
$1,039,000.00
Revenue This Year
$10.92
$730.30
Revenue Next Year
$7.31
$179.48
P/E Ratio
$62.53
N/A
Revenue Growth
12.83
N/A
52 Week Low
$29.25
$24.10
52 Week High
$58.50
$57.99

Technical Indicators

Market Signals
Indicator
KGS
CRNX
Relative Strength Index (RSI) 65.75 28.30
Support Level $33.49 $35.43
Resistance Level $58.50 $37.23
Average True Range (ATR) 1.96 1.60
MACD -0.45 0.01
Stochastic Oscillator 68.88 8.48

Price Performance

Historical Comparison
KGS
CRNX

About KGS Kodiak Gas Services Inc.

Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: